Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | TRANSCEND-CLL-004 update from EHA: liso-cel for R/R CLL

William Wierda • 13 Jun 2019
EHA 2019
Chronic Lymphocytic Leukemia Leukemia CAR-T Lisocabtagene maraleucel
TRANSCEND-CLL-004

William Wierda, MD, PhD, from The University of Texas MD Anderson Cancer Center, Houston, TX, explains the update on the TRANSCEND-CLL-004 trial (NCT03331198) of lisocabtagene maraleucel at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from William Wierda

1:12
Primary analysis of TRANSCEND-CLL-004: liso-cel in R/R CLL
William Wierda • 10 Jun 2023
2:08
Disease characteristics impacting treatment decisions in CLL
William Wierda • 10 Jun 2023
2:20
Genomic evolution and resistance to pirtobrutinib in CLL: insights from the BRUIN study
William Wierda • 10 Jun 2023
1:07
The current status of liso-cel in CLL and updates from the TRANSCEND-CLL-004 trial
William Wierda • 28 Sep 2022

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals